RT Journal Article
SR Electronic
T1 Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.25.22274294
DO 10.1101/2022.04.25.22274294
A1 Suntronwong, Nungruthai
A1 Kanokudom, Sitthichai
A1 Auphimai, Chompoonut
A1 Assawakosri, Suvichada
A1 Thongmee, Thanunrat
A1 Vichaiwattana, Preeyaporn
A1 Duangchinda, Thaneeya
A1 Chantima, Warangkana
A1 Pakchotanon, Pattarakul
A1 Chansaenroj, Jira
A1 Puenpa, Jiratchaya
A1 Nilyanimit, Pornjarim
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Sudhinaraset, Natthinee
A1 Wanlapakorn, Nasamon
A1 Poovorawan, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/04/28/2022.04.25.22274294.abstract
AB Background The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion because it harbors mutations even in individuals with complete vaccination. Here, we examine the capability of the booster vaccination to induce neutralizing antibodies (NAbs) against omicron (BA.1 and BA.2) and T-cell responses.Methods A total of 167 participants primed with heterologous CoronaVac/AZD1222 were enrolled to receive AZD1222, BNT162b2, or mRNA-1273 as a booster dose. Reactogenicity was recorded. Binding antibody, neutralizing antibody (NAb) titers against omicron BA.1 and BA.2, and total interferon gamma (IFN-γ) post-booster responses were measured.Results A substantial loss in neutralizing potency to omicron variant was found at 4 to 5 months after receiving the heterologous CoronaVac/AZD1222. Following booster vaccination, a significant increase in binding antibodies and neutralizing activities toward delta and omicron variants was observed. Neutralization to omicron BA.1 and BA.2 were comparable, showing the highest titers after boosted mRNA-1273 followed by BNT162b2 and AZD1222. Notably, boosted individuals with mRNA vaccines could induce T cell response. Reactogenicity was mild to moderate without serious adverse events.Conclusions Our findings highlight that the booster vaccination could overcome immunity wanes and provide adequate NAbs coverage against omicron BA.1 and BA.2.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20211120002Funding StatementThis work was supported by the National Research Council of Thailand, the Health Systems Research Institute, the Center of Excellence in Clinical Virology of Chulalongkorn University, and King Chulalongkorn Memorial Hospital. Thaneeya (Duangchinda) Roytrakul was supported by National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613). Nungruthai Suntronwong reports that financial support was also provided by the Second Century Fund Fellowship of Chulalongkorn University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB numbers 871/64) and performed under the Declaration of Helsinki and Good Clinical Practice principles. This study was registered with the Thai Clinical Trials Registry (TCTR20211120002). All participants signed a written consent before being enrolled in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript